Lexicon Pharma (LXRX) to Present LX1031 Phase 2 Results at GASTRO 2009
Tweet Send to a Friend
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), announced today that top-line data from its Phase 2 clinical study with LX1031 in patients ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
